Trial Profile

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DFC413 and Safety and Imaging Properties of [68Ga]Ga-NNS309 in Patients With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium-68 NNS309 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Ductal carcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Novartis

21 Jan 2026 Planned End Date changed from 24 Apr 2029 to 9 May 2029.
21 Jan 2026 Planned primary completion date changed from 24 Apr 2029 to 9 May 2029.
17 Dec 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com